Meiji Seika Pharma Co., Ltd. plans to establish a local subsidiary in Singapore in spring 2026 to strengthen its commercial operations in the ASEAN region, with a focus on pharmaceuticals and vaccines covering infectious diseases, haematologic cancers and lifestyle-related conditions.

• Strategic expansion: New subsidiary will serve as a regional hub for commercialisation, marketing and distribution across ASEAN.
• Operational timeline: Expected to commence operations in spring 2026.
• Business focus: Leveraging decades of experience in Thailand and Indonesia to accelerate regional growth.

This summary is based on a corporate press release by Meiji Seika Pharma.